TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01509937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: body bioimpedance spectroscopy device
Description: Name of the device is BCM from Fresenius Medical Care D GmbH

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Device
Description: participants in control arm will not receive BCM measurement.
Study: NCT04844996

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgical induction of endometriotic explants
Description: Surgical induction of endometriosis was done as: A 5-cm vertical midline incision was made and a distal segment 1 cm in length of the right uterine horn was resected. The segment was split longitudinally, and a 5 X 5 mm piece was sectioned.~This piece of uterine tissue was transplanted without removing the myometrium onto the inner surface of the right abdominal wall with the serosal surface apposed and secured with single nonabsorbable 5-0 polypropylene suture at the middle to the abdominal wall. The abdominal incision was closed in two layers~Drug administration:~Vehicle treatment (1 mL/kg/day saline) was administered orally to the control group with the gavage methodology. Ezetimibe (1 mg/kg/day (Ezetrol®, Merck Sharp Dohme, Istanbul, Turkey) was administered orally with gavage methodology to the rats in the study for 28 days postoperatively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical induction of endometriotic explants
Description: Surgical induction of endometriosis was done as: A 5-cm vertical midline incision was made and a distal segment 1 cm in length of the right uterine horn was resected. The segment was split longitudinally, and a 5 X 5 mm piece was sectioned.~This piece of uterine tissue was transplanted without removing the myometrium onto the inner surface of the right abdominal wall with the serosal surface apposed and secured with single nonabsorbable 5-0 polypropylene suture at the middle to the abdominal wall. The abdominal incision was closed in two layers~Drug administration:~Vehicle treatment (1 mL/kg/day saline) was administered orally to the control group with the gavage methodology. Ezetimibe (1 mg/kg/day (Ezetrol®, Merck Sharp Dohme, Istanbul, Turkey) was administered orally with gavage methodology to the rats in the study for 28 days postoperatively
Study: NCT01600014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate gel, 0.015%
Description: Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
Study: NCT01637675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg sildenafil citrate by mouth
Description: 20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth
Description: sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
Study: NCT02664766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week. Participants will be recording their daily alcohol consumption. Participants will also undergo three trials of acute exercise (before, at the 4th week and at the 8th week of exercise training) in order to investigate whether exercise training can lead to changes in acute responses to exercise. Each trial involves 30 min of exercise on a cycle ergometer at 50-60% HRR.
Study: NCT02682433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diagnostic hysteroscopy
Description: Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diagnostic sonar test
Description: Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
Study: NCT02913508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab intravenous injection
Description: Vedolizumab intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab intravenous injection
Description: Vedolizumab intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab intravenous injection
Description: Vedolizumab intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab subcutaneous injection
Description: Vedolizumab subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab subcutaneous injection
Description: Vedolizumab subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab subcutaneous injection
Description: Vedolizumab subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab subcutaneous injection
Description: Vedolizumab subcutaneous injection
Study: NCT03659968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity training
Description: brisk walking on treadmill and exercises of muscular strengthening with varying durations and intensities depending on physical capabilities of patients
Study: NCT03882216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: soft tissue augmentation using pouch technique
Description: crestal incision with split thickness flap without vertical releasing incision till the mucogingival line then apply the harvested connective tissue graft through it.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: soft tissue augmentation using modified pouch technique
Description: tunneling will be done at the pontic site till the mucogingival line then a distant vertical incision near the tunnel at the lining mucosa where the harvested connective tissue graft wll be applied .
Study: NCT03697837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Management Training
Description: The online digital parent training (DPT) program consists of 8 self-guided courses that take approximately 10 minutes to complete and include text and animated parent-child simulations. The courses are designed to closely parallel the content of existing evidence-based parent management training approaches that exist in numerous parenting books.
Study: NCT03875560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC14
Description: recombinant chimeric anti-human CD14 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC14
Description: recombinant chimeric anti-human CD14 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC14
Description: recombinant chimeric anti-human CD14 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC14
Description: recombinant chimeric anti-human CD14 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC14
Description: recombinant chimeric anti-human CD14 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive
Study: NCT02491619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthodontic decompensation
Description: Evaluation of the correlation between bone thickness and tooth inclination previously and after orthodontic treatment of decompensation due to orthognathic surgery
Study: NCT00822861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI ASM8
Description: 4 mg/mL, 1 mg BID for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI ASM8
Description: 4 mg/mL, 2 mg BID for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI ASM8
Description: 4 mg/mL, 4 mg BID for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI ASM8
Description: 4 mg/mL, 8 mg OD for 4 days
Study: NCT04608578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Silver
Description: A serious game to improve mental health in youth
Study: NCT00552227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruboxistaurin
Description: oral 32 mg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04103411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24h-Ambulatory Blood Pressure
Description: Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24h-Ambulatory Blood Pressure
Description: Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.
Study: NCT00730288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric dengue serotype (1, 2, 3, 4)
Description: 0.5 mL, Subcutaneous, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric dengue serotype (1, 2, 3, 4)
Description: 0.5 mL, Subcutaneous, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric dengue serotype (1, 2, 3, 4)
Description: 0.5mL, Subcutaneous, 1 dose
Study: NCT02373735

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: crystalloid
Description: Group A (SVV \<10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: crystalloid
Description: Group A (SVV \<10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: colloid
Description: Group A (SVV \<10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is \> 20%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: colloid
Description: Group A (SVV \<10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is \> 20%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mannitol
Description: Group B (SVV 10-20%): infuse mannitol 0.5 g/kg if SVV is \< 10%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lasix
Description: Group B (SVV 10-20%): infuse lasix 5 mg if SVV is \< 10%
Study: NCT00080288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg/day
Description: Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets once daily
Study: NCT01215682

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: 2000 IU/day of vitamin D3 as a once-daily dose
Study: NCT02953626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother Matters Online Postpartum Support Group
Description: Mother Matters is a 10-week online support group for women with postpartum depression. It involves: 1) A private, online forum that can be accessed by participants 24-hours per day. During regular business hours (9:00 am to 5:00 pm on weekdays) it is moderated by a psychotherapist, and there is a weekly moderated live chat hour; 2) Weekly topics with readings are provided with questions to prompt discussion on the online forum. Topics incorporate symptom management (i.e. Interpersonal Therapy, Cognitive Behavioural Therapy) and affect regulation strategies (i.e. Mindfulness, DBT) with a supportive counselling approach. External resources related to each week's topic, are also shared.
Study: NCT03267680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Given PO
Study: NCT01418378

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma CR150
Description: Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma CR
Description: Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
Study: NCT00788671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-Releasing Intrauterine System
Description: Undergo placement of a levonorgestrel-releasing intrauterine system
Study: NCT03267680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IRX-2
Description: Given via submucosal injection or SC
Study: NCT01215682

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sweetened water
Study: NCT03267680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Given zinc-containing multivitamin PO

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Given zinc-containing multivitamin PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given via submucosal injections or SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT01658787

Intervention type: DEVICE
Intervention: Endovascular aortic repair
Description: Treatment with Gore Endovascular Aortic Products.
Study: NCT00388414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 30-60mg of duloxetine daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill once daily
Study: NCT01156701

Intervention type: DRUG
Intervention: Receiving a prescription of Relenza for prophylaxis
Description: Receiving a prescription of Relenza for prophylaxis

Intervention type: DRUG
Intervention: Receiving a prescription of Relenza for prophylaxis
Description: Receiving a prescription of Relenza for prophylaxis

Intervention type: OTHER
Intervention: No prophylaxis with Relenza
Description: No prophylaxis with Relenza

Intervention type: OTHER
Intervention: No prophylaxis with Relenza
Description: No prophylaxis with Relenza
Study: NCT00778466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride 1000 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin hydrochloride 1000 mg tablets
Study: NCT02082054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSE 120 mg, CM 8 mg, Atr 0.36 mg
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSE 120 mg, CM 8 mg, Atr 0.24 mg
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSE 120 mg, CM 8 mg, Atr 0.12 mg
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PSE 120 mg, CM 8 mg
Description: Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0.24 mg
Description: Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side
Study: NCT02541929

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Docosahexaenoic acid
Study: NCT01220557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIMAS
Description: PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DTTP
Description: The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
Study: NCT02854540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogel electrode-based iontophoresis
Description: Hydrogel was administered through iontophoresis, a process of transdermal drug delivery by use of a voltage gradient on the skin.
Study: NCT03634774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHOICE+ Training Program
Description: CHOICE+ is a program where team members and other stakeholders are engaged in making changes to dining in a long term care home to improve the experience. An external coach supports behaviour change.

Intervention type: OTHER
Group type: OTHER
Intervention: CHOICE+ Training Program
Description: CHOICE+ is a program where team members and other stakeholders are engaged in making changes to dining in a long term care home to improve the experience. An external coach supports behaviour change.

Intervention type: OTHER
Group type: OTHER
Intervention: CHOICE+ Training Program
Description: CHOICE+ is a program where team members and other stakeholders are engaged in making changes to dining in a long term care home to improve the experience. An external coach supports behaviour change.
Study: NCT02866253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: Interventional patients should take DHEA 25mg tid 12weeks before enter the IVF cycle.
Study: NCT02824276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone or morphine sulfate immediate release (MSIR)
Description: Oxycodone or morphine sulfate immediate release (MSIR)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Treatment
Description: Lactose (Appearance and Weight-matched placebo capsules)
Study: NCT04989270

Intervention type: PROCEDURE
Intervention: General Anesthesia
Description: General anesthesia with intubation, ventilation, intravenous and inhalational anesthetics, opioids and muscle paralysis

Intervention type: PROCEDURE
Intervention: Regional Anesthesia
Description: Spinal Anesthesia, Epidural Anesthesia
Study: NCT03906370

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic criteria for MS
Description: The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
Study: NCT04895267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-field thoracic magnetic stimulation (LF-ThMS)
Description: A 30 minutes session of low-field thoracic magnetic stimulation (LF-ThMS) is planned for each participant.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-field thoracic magnetic stimulation (LF-ThMS)
Description: A 30 minutes session of low-field thoracic magnetic stimulation (LF-ThMS) is planned for each participant.
Study: NCT01437592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
Study: NCT02449538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus 10 mg qd daily one cycle is 28days.
Study: NCT03176693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxybenzamine
Description: Non-selective alpha blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Selective alpha blocker